Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Rapid and significant improvements observed with topical ruxolitinb in cutaneous lichen planus
JOURNALS
Start Learning
FDA approval of nemolizumab gives new treatment option for prurigo nodularis
JOURNALS
Start Learning
Introducing our newest Expert Faculty member: A leader in urticaria, drug allergies and angioedema
Layer of cells, human skin cells, medical illustration
JOURNALS
Start Learning
Could dupilumab help improve height in children with severe atopic dermatitis?
Early-onset atopic dermatitis
JOURNALS
Start Learning
Specific cord-blood DNA methylation patterns associated with risk of early-onset atopic dermatitis
JOURNALS
Start Learning
New study links rosacea with increased risk of malignant melanoma
touchEXPERT BRIEFING
Start Learning
Advances in the treatment of CSU
Sponsored content
David Rosmarin: Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
CONFERENCE HUB
Start Learning
Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
touchMEETING HIGHLIGHTS
Start Learning
Pathophysiological mechanisms and emerging concepts in the management of Type 2 dermatological diseases
Sponsored content
Dr Raj Chovatiya (Associate Professor at Rosalind Franklin University Chicago, IL, USA) at the 2025 American Academy of Dermatology (AAD) Annual Meeting to discuss key late-breaking data on three promising therapies—ESK001, icotrokinra, and rocatinlimab—for psoriasis and atopic dermatitis.
CONFERENCE HUB
Start Learning
#AAD25: Essential updates in atopic dermatitis and psoriasis

to view Favourites, Keep Notes and Track CME Credits

Favourites
#AAD25: Essential updates in atopic dermatitis and psoriasis
View
Ruxolitinib cream shows safe and lasting control in paediatric atopic dermatitis
View
Global impact, Brazilian roots: Prof. Ensina’s journey leading innovation in allergy and immunology
View
From Clinic to CNN: Dr. Shari Lipner’s Journey in Advancing Nail Disorders and Mentoring Future Leaders
View
Honouring Prof. Marcus Maurer
View
Could dupilumab help improve height in children with severe atopic dermatitis?
View
Novel, oral TYK2 inhibitor, ESK-001, reports improved efficacy with prolonged use in plaque psoriasis
View
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
View
Introducing our newest Expert Faculty member: A leader in urticaria, drug allergies and angioedema
View
Breakthroughs in melanoma: Highlights from ASCO 2024
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup